Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 7 (5), 441-3

Therapeutics From Adult Stem Cells and the Hype Curve


Therapeutics From Adult Stem Cells and the Hype Curve

Greg Maguire. ACS Med Chem Lett.


The Gartner curve for regenerative and stem cell therapeutics is currently climbing out of the "trough of disillusionment" and into the "slope of enlightenment". Understanding that the early years of stem cell therapy relied on the model of embryonic stem cells (ESCs), and then moved into a period of the overhype of induced pluripotent stem cells (iPSCs), instead of using the model of 40 years of success, i.e. adult stem cells used in bone marrow transplants, the field of stem cell therapy has languished for years, trying to move beyond the early and poorly understood success of bone marrow transplants. Recent studies in the lab and clinic show that adult stem cells of various types, and the molecules that they release, avoid the issues associated with ESCs and iPSCs and lead to better therapeutic outcomes and into the slope of enlightenment.

Conflict of interest statement

The authors declare the following competing financial interest(s): Part owner of BioRegenerative Sciences, Inc, a stem cell therapeutics company.


Figure 1
Figure 1
Hype curve for regenerative therapeutics.
Figure 2
Figure 2
MicroRNA: Example of the molecules released from adult stem cells.

Similar articles

See all similar articles

Cited by 3 articles